期刊文献+

右丙亚胺联合参麦注射液对减少急性白血病化疗中心脏毒性的影响 被引量:4

Effect of Combination of Dexrazoxane and Shenmaion Injection on Reducing Cardiac Toxicity during Acute Leukemia Chemotherapy
在线阅读 下载PDF
导出
摘要 目的观察比较右丙亚胺注射液单用、参麦注射液单用及两药联合使用对急性白血病患者化疗期间心脏毒性的影响.方法将105例已明确诊断为急性白血病的患者随机分为3组,每组35例,每组患者均应用含有蒽环类药物的化疗方案.A组(右丙亚胺组)在应用蒽环类药物化疗前30 min将右丙亚胺注射液快速静脉滴注;B组(参麦注射液组)对化疗患者给予参麦注射液保护心脏治疗,用法为50 mg/d静脉滴注;C组(联合用药组)在化疗同时联合应用右丙亚胺及参麦注射液保护心脏,每组药物均在化疗期间使用,化疗结束后停止使用.结果比较3组患者化疗前后的心电图、心肌酶及左心室射血分数变化,观察其心脏损害的程度.结果表明:C组患者各种心脏损害的指标均低于A,B两组.结论右丙亚胺及参麦注射液联合应用对于接受以蒽环类药物为基础的化疗方案的患者能明显减轻其心脏毒性作用,可作为降低蒽环类药物心脏毒性的新途径. Objective To observe and compare the toxicity during acute leukemia chemotherapy. Method effects of dexrazoxane and Shenmai injection on cardiac divided into three groups, with 35 patients in each 105 patients diagnosed as group. All the patients acute leukemia were randomly accepted chemotherapy with anthracycline. Group A: Dexrazoxane group, dexrazoxane injection was rapidly administrated 30 minutes before chemotherapy. Group B:Shenmai injection group, the patients were given Shenmai intravenous infusion to protect their hearts with 50 mg per day. Group C:eombination group, dexrazoxane and Shenmai injections were combined to protect heart during chemotherapy. All the injections were administrated during chemotherapy, and were removed at the end of the treatment. Results Compared the changes of myocardial enzyme amount, ECG and left ventricular ejection fraction in the patients, and observed the degree and proportion of heart damage. The results showed that the heart damage index of group C was lower than that of group A and B. Conclusion Thecombination of dexrazoxane and Shenmai injections can significantly reduce cardiac toxicity in the patients accepted chemotherapy based on anthracycline, which will provide a new way to reduce the cardiotoxicity of anthracycline.
出处 《北华大学学报(自然科学版)》 CAS 2015年第3期335-337,共3页 Journal of Beihua University(Natural Science)
基金 吉林省科技发展计划项目(20070505)
关键词 蒽环类药物 心脏毒性 右丙亚胺 参麦注射液 anthracycline cardiotoxicity dexrazoxane Shenmai Injection
作者简介 王璇(1974-),女,硕士,副主任医师,主要从事各种疑难血液系统疾病研究,E-mail:46387000@qq.com.
  • 相关文献

参考文献9

  • 1邵维维,邵宗鸿.蒽环类药物的心脏毒性及防治进展[J].中国实用内科杂志,2008,28(9):779-781. 被引量:34
  • 2Blowers E,Hall K. Managing adverse events in the use ofbevacizumab and chemotherapy[J]. Nurs,2009,18(6):351-356.
  • 3Ramirez M A,Sobrino-Cossio S,Mora-Levy J G,et al.Loss of expression of DNA mismatch repair proteins inaberrant crypt ooci identified in vivo by magnifyingcolonoscopy in subjects with hereditary nonpolyposic andsporadic colon rectal cancer[J]. J Gastrointest Cancer,2012,12(2):209-214.
  • 4Jones A L,Barrett-Lee P J. Management of cardiac healthin trastuzumab-treated patients with breast cancer:updateduntired kingdom national cancer research instituterecommendations of monitoring[J]. Cancer,2011,100(5):684-692.
  • 5吕俊,丁念,朱家蔷,高霞.蒽环类药物心脏毒性及其预防的研究进展[J].中国医院药学杂志,2008,28(15):1302-1303. 被引量:19
  • 6Junjing Z,Yan Z, Baolu Z. Scavenging-effects of dexrazoxaneon free radicals [J]. J Clin Biochem Nutr,2010,47(3):238-245.
  • 7郝文.参麦注射液对阿霉素心脏毒性反应的防治作用[J].中医药临床杂志,2007,19(1):5-6. 被引量:9
  • 8BLOWERS E,Haii K. Managing adverse events in the use ofbevacizumab and chemotherapy [J]. Nurs,2011,12 (6):439-440.
  • 9Yeh E T,Tong A T,Lenihan D J,et al. Cardiovascularcomplications of cancer therapy:diagnosis,pathogenesis,and management [J]. Circulation, 2004, 109 ( 25 ):3122-3131.

二级参考文献37

  • 1杨学义,宿燕岗,陈灏珠.辅酶Q_(10)的药理和临床应用[J].中国药理学通报,1994,10(2):88-91. 被引量:13
  • 2范毅敏,李静,陈纯,李文益,甄宇峰,沈娜君.1,6-二磷酸果糖治疗蒽环类药物心肌损害的疗效[J].岭南急诊医学杂志,2005,10(4):244-245. 被引量:4
  • 3王建智,刘庆安西安交通大学第一医院外科,王建国.黄芪注射液拮抗阿霉素致小鼠心脏毒性的作用[J].第四军医大学学报,2006,27(4):366-366. 被引量:11
  • 4胥彬,韩锐,潘启超.我国肿瘤药理学研究十年进展[J].中国药理学通报,1996,12(1):7-11. 被引量:4
  • 5孙燕 周际昌.临床肿瘤内科手册(第3版)[M].北京:人民卫生出版社,1997.53-54.
  • 6Germanakis I, Kalmanti M, Parthenakis F, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide level with left ventricle mass in children treated with anthracyclines[ J]. Int J Cardiol,2006,108:212 -215.
  • 7Malty M, Espie M, Llombart A, et al. Muhicenter randomized Phase Ⅲ study of the cardioprotective effect of dexrazoxane in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy[ J]. Ann Onco1,2006 ,17 :614 - 622.
  • 8Sterba M, Popelova O, Simunek T, et al. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH) [ J ]. Toxicology ,2007,253 ( 3 ) : 150 - 166.
  • 9Kaiserva H, Simunek T, van der Vijgh W J, et al. Flavonoids as protectors against doxorubicin cardiotoxicity : role of iron chelation, an-tioxidant activity and inhibition of carbonyl reductase [ J ]. Biochim Biophys Acta,2007,1772 : 1065 - 1074.
  • 10Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the eardiotoxic mechanisms to management[ J], Prag Cardiovase Dis,2007,49 (5) :330 - 352.

共引文献53

同被引文献17

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部